FDA Approves Larger Idelvion Vial Size for Hemophilia B Patients Requiring Higher Doses
The U.S. Food and Drug Administration has approved a larger vial size — 3,500 IU — of CSL Behring’s…
Articles by Iqra Mumal, MSc
Not Having to Refrigerate a Clotting Factor Increases Satisfaction with It, Study Finds
Hemophilia A patients who do not refrigerate their bleeding prevention therapy are more satisfied with it and report fewer restrictions…
Workers with Hemophilia More Likely to Have Stroke or Joint Disease, Study Shows
Workers with hemophilia are at a much higher risk of stroke, developing a joint disease, or needing a knee or…
Medtep Hemophilia Helps Patients Adhere Better to Preventive Treatment, Study Shows
Researchers report that the Medtep Hemophilia online platform helped hemophilia patients improve their adherence to preventive treatment, while increasing their…
Bilateral Total Knee Arthroplasty in Hemophilia Patients is Safe and Cost-Effective, Study Suggests
New research shows that bilateral total knee arthroplasty — or reconstruction of the joint — is a safe and cost-effective…
Nuwiq Seen as Safe and Effective Pre-surgical Treatment for People with Severe Hemophilia A
Nuwiq, a fourth-generation genetically engineered version of blood-clotting factor VIII, is a safe and effective way of controlling bleeding…
FDA Approves Hemlibra to Treat for Hemophilia A Patients with Factor VIII Inhibitors
The U.S. Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or lessen…
uniQure to Advance AMT-061 Gene Therapy for Hemophilia B to Clinical Trial in 2018
uniQure plans to advance its investigational gene therapy AMT-061 into a pivotal study in 2018 for patients with severe and…
Novimmune Grants Shire Global Rights to Its Antibody-based Hemophilia A Treatment
Shire has acquired worldwide rights to the antibody-based therapy that Novimmune developed as a treatment for hemophilia A. Geneva-based Novimmune creates…
Europe Grants Orphan Drug Status to CB 2679d to Prevent Hemophilia B Bleeding Episodes
European regulators have granted orphan drug status to CB 2679d, a hemophilia B therapy that Catalyst Biosciences developed to prevent bleeding…